Tag: drug safety
-
The real clinical cost of in-vivo gene editing is not potency but irreversibility — reading the MAGNITUDE hepatotoxicity signal, the death, and asymmetric risk by evidence tier
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. Across Parts 0–3 this series showed that in-vivo editing has already matched siRNA/ASO on the headline metric — knockdown depth (PCSK9 −88%, TTR −87%, Z-AAT…
-
Same primary endpoint, opposite headlines: reading AI-designed drug readouts (rentosertib, EXS-21546, BEN-2293) — Part 3
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. The 30-second version What. This part dissects individual AI-designed clinical readouts along a single axis: primary endpoint vs. headline. The decisive fact of framing asymmetry: rentosertib (headlined “positive”) and BEN-2293 (headlined “failed”) both…
Uthando Nethemba 